Google News

By Anonymous User · February 24, 2026

Gilead Sciences to Acquire Arcellx to Maximize Long-Term Potential of Anito-cel  Gilead SciencesThis Biotech Stock Is Having Its Best Day Ever. Gilead Sciences Is Buying It.  Barron'sGilead to acquire cancer therapy developer Arcellx for up to $7.8 billion  ReutersHere's Why Shares of Arcellx Are Up Almost 80% Today  Yahoo FinanceGilead Sciences to Buy Arcellx in Deal Valued at $7.8 Billion  WSJ